Instructions for Gliatilin (choline alfoscerate) solution
ATC Codes
N07AX02 choline alfoscerate
Clinical and pharmacological groups / Group affiliation
Nootropic agent. Central acting cholinomimetics.
Active substance Gliatilin
choline alfoscerate
Pharmacotherapeutic group
Nootrop
Pharmacological effect Gliatilin
Cholinomimetics. It is a precursor of acetylcholine. It affects mainly cholinergic receptors in the central nervous system. Glycerophosphate, which is produced by the breakdown of choline alfoscerate, is a precursor of phospholipids (phosphatidylcholine) in the neuronal membrane. Facilitates nerve impulse transmission in cholinergic neurons and improves plasticity of neuronal membranes.
Indications choline alfoscerate
Acute period of traumatic brain injury with predominantly stem-level involvement, chronic cerebrovascular insufficiency (discirculatory encephalopathy)
Dementia syndrome of various origins, including
Alzheimer disease, ischemic stroke (early and late recovery), Gettington chorea, and senile pseudomelancholy
Mode of application, course and dosage Gliatilin
Oral: 400 mg three times a day, treatment for three to six months. Intramuscular or intravenous: 1 gram per day.
Nosology choline alfoscerate (ICD codes)
F00
Dementia Alzheimer's type
F01
Vascular dementia
F03
Dementia, unspecified
F07
Personality and behavior disorders resulting from brain disease, damage, or dysfunction
G10
Huntington's chorea
G93.4
Encephalopathy, unspecified
I63
Brain infarction
S06
Intracranial injury
